XNAS · Healthcare · Biotechnology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | -0.55 | -0.71 | -29.09% | $1.1M | ❌ Miss | -0.98% | -3.86% | — |
| 2026-02-27 | Q4 2025 | -0.59 | -0.51 | +13.56% | $2.3M | ✅ Beat | +1.59% | +5.24% | +8.78% |
| 2025-11-14 |
| Q3 2025 |
| -0.56 |
| -0.57 |
| -1.79% |
| $1.7M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | -0.46 | -0.54 | -17.39% | $0 | ❌ Miss | -0.21% | +3.42% | +35.57% |
| 2025-05-13 | Q1 2025 | -0.28 | -0.45 | -60.71% | $52,000 | ❌ Miss | -0.04% | +9.84% | +9.59% |
| 2025-03-28 | Q4 2024 | -0.39 | -0.46 | -17.95% | $456,000 | ❌ Miss | — | — | — |
| 2024-11-12 | Q3 2024 | -0.36 | -0.30 | +16.67% | $0 | ✅ Beat | -4.95% | -11.30% | -21.93% |
| 2024-08-08 | Q2 2024 | -0.37 | -0.28 | +24.32% | $0 | ✅ Beat | +1.17% | +3.49% | +14.11% |
Showing last 8 quarters.